echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Abwi is about to complete the US $63 billion acquisition of Erjian's business in two parts

    Abwi is about to complete the US $63 billion acquisition of Erjian's business in two parts

    • Last Update: 2020-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 8, aberway announced that it would create a new global business company, Allergan aesthetics, after the completion of the acquisition, which is expected to be completed in the first quarter of this year Erjian aesthetics will operate as a new global specialized company, mainly leading medical beauty products, including Botox medical beauty products, juvederm, coolsculping, etc The company's global business headquarters will be located in erwan City, California, which is now in the charge of Carrie strom, senior vice president of American medical beauty of Elkem After the acquisition, she will become senior vice president of Elkem and President of Elkem aesthetics, responsible for the global business of the new company, and report directly to Richard A Gonzalez, President and CEO of Elkem While Elgin's eye care and specialty medicine business (including Botox medical products, central nervous system, women's health and digestive products) will be integrated into the existing organizational structure of Elgin According to Elgin, several relevant directors of Elgin have accepted new positions in the future According to today's announcement, Richard A Gonzalez will continue to be chairman and CEO of the new company after the merger, and Carlos Alban will continue to be vice chairman and chief commercial officer On June 25 last year, abbvie and Allergan announced that the two companies had signed a final transaction agreement, under which they would acquire eljian in the form of cash and stock transactions, with a value of about $63 billion based on the closing price of $78.45 of common shares on June 24.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.